Press Releases

Business & Solutions

bioMérieux receives De Novo FDA Authorization for its BIOFIRE® Joint Infection (JI) Panel

bioMérieux, a world leader in the field of in vitro diagnostics, today announces that its BIOFIRE® Joint Infection (JI) Panel has received De Novo authorization from the US Food and Drug Administration (FDA). This panel tests for 31 pathogens implicated in most acute joint infections, and also includes 8 antimicrobial resistance (AMR) genes.

Antimicrobial Resistance

Specific Diagnostics acquisition

bioMérieux, a world leader in the field of in vitro diagnostics, announces that it has entered into an agreement to acquire Specific Diagnostics, a privately held U.S. based company that has developed a rapid antimicrobial susceptibility test (AST) system that delivers phenotypic AST directly from positive blood cultures.

Financial Information

First-Quarter 2022 Business Review

bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the three months ended March 31th, 2022.

Business & Solutions

bioMérieux receives FDA 510(k) clearance for its VITEK® MS PRIME new MALDI-TOF mass spectrometry identification system

bioMérieux, a world leader in the field of in vitro diagnostics, announces that VITEK® MS PRIME, its new MALDI-TOF mass spectrometry identification system, has received 510(k) clearance from the U.S. ...

Financial Information

bioMérieux – 2021 Financial Results

The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on March 1 under the chairmanship of Alexandre Mérieux and approved the audited consolidated financial st...

Business & Solutions

MYACUTECASE™, a free mobile application by bioMérieux to support clinicians in decision-making and monitoring of patients using emergency and critical care diagnostics

bioMérieux, a world leader in the field of in vitro diagnostics, launches MYACUTECASETM. This mobile application, the first of a kind developed by bioMérieux, is an aid in the interpretation of VIDAS®...

Partnerships

French multidisciplinary consortium ARPEGE awarded public funding of close to €9 million to fight antibiotic resistance

The ARPEGE project aims to develop a set of solutions to strengthen the ability of healthcare institutions to fight antibiotic resistance. The consortium, led by Antabio, has been awarded close to €9 ...

Corporate Social Responsibility

Corporate Social Responsibility: bioMérieux recently received a series of official recognitions from independent third parties

bioMérieux, a world leader in the field of in vitro diagnostics, recently received a series of official recognitions for its achievements in Corporate Social Responsibility (CSR) from independent thir...

Financial Information

bioMérieux – Increased outlook for full-year 2021

bioMérieux, a world leader in the field of in vitro diagnostics, today released its adjusted outlook for full-year 2021. In light of stronger than expected respiratory panels sales in Q4, full-year 20...

Business & Solutions

bioMérieux molecular tests efficiently detect SARS-CoV-2 Omicron variant

As the incidence of infections with the SARS-CoV-2 Omicron variant (B.1.1. 529) continues to rise, there is much concern about diagnostic tests ability to efficiently detect this multi-mutated form of...

Partnerships

Baxter and bioMérieux announce CE mark for NEPHROCLEAR™ CCL14 test to predict persistent severe acute kidney injury

Baxter International Inc. (NYSE:BAX), a global leader in acute care, and bioMérieux (EPA:BIM), a global leader in in vitro diagnostics, today announced the CE marking of the NEPHROCLEAR™ CCL14 Test. T...

bioMérieux – Third-Quarter 2021 Business Review

bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the nine months ended September 30, 2021.

A survey in 5 European countries about sepsis demonstrates the lack of awareness and an expectation for faster diagnostic capabilities

On World Sepsis Day, bioMérieux, a world leader in the field of in vitro diagnostics, and the UK Sepsis Trust, an internationally renowned charity committed to help put an end to preventable deaths fr...

bioMérieux – First-Half 2021 Results

The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on August 31 under the chairmanship of Alexandre Mérieux and approved the consolidated financial statemen...

bioMérieux launches EPISEQ® SARS-COV-2, a cloud-based software application for the epidemiological surveillance of SARS-CoV-2 variants

bioMérieux, a world leader in the field of in vitro diagnostics, has launched EPISEQ® SARS-COV-2, a genomic software solution to support microbiology labs in identification and reporting from raw sequ...